Corrigendum to "Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon S-S, Kavanagh D and Haller H; on behalf of the 311 Study Group. The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2020;97:1287-1296.

Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann

Rondeau, Eric; Scully, Marie; Ariceta, Gema; Barbour, Tom; Cataland, Spero; Heyne, Nils; Miyakawa, Yoshitaka; Ortiz, Stephan; Swenson, Eugene; Vallee, Marc; Yoon, Sung-Soo; Kavanagh, David; Haller, Hermann.

Kidney Int ; 99(5): 1244, 2021 May.

Article in En | MEDLINE | ID: mdl-33892867

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Kidney Int Year: 2021 Document type: Article

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Kidney Int Year: 2021 Document type: Article